FRCPath Haem Part 1 MCQ-Oncology 25

NICE 2024 recommends polatuzumab vedotin + R-CHP as a first-line option for which patient group?

• All patients with DLBCL
• Patients with double-hit DLBCL lymphoma
• Patients with relapsed/refractory DLBCL
• Patients with untreated DLBCL and IPI ≥2

See All Options